Cardiomyopathy, Dilated, Heart Failure
Conditions
Brief summary
The purpose of this research is to investigate the effect of using this surgical technique in conjunction with bypass surgery to improve heart function and size, as well as decrease the possibility of future mitral valve surgery.
Detailed description
The Sling is used to draw together the ventricular walls at the base of the papillary muscles. This technique has previously been used in conjunction with mitral valve surgery, and has shown significant benefits for the patients. The reduction in the lateral inter-papillary muscle separation and in the left ventricular volume provided by this technique is expected to improve ventricular function, limit progression of ventricular dilation, and avoid progression of MR when performed without mitral valve surgery in patients with symptomatic ventricular dilation.
Interventions
DEVICEPapillary Muscle Sling
The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.
PROCEDURECABG surgery
Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
Sponsors
University of Miami
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients with symptomatic heart failure with reduced ejection fraction and either ischemic or non-ischemic cardiomyopathies, referred for CABG surgery. Suitability for the ventricular sling procedure is determined by the surgeon and or cardiologist, using some or all the criteria described below: * Left ventricular end diastolic diameter is greater than or equal to 55mm. * Ejection fraction ≥20% and ≤40% * FMR grade ≤ 2+ (≤ mild FMR) as defined by the guidelines of the American society of echocardiography at the time of the study approval (via a transthoracic or transesophageal echo). * End-systolic Interpapillary muscle distance ≥ 20mm * Cardiomyopathy of ischemic or non-ischemic origins. * Able to sign informed consent and release of medical information forms, or able to assign a legal representative who can sign on the patient's behalf.
Exclusion criteria
* Any evidence of structural (chordal or leaflet) mitral lesions. * Planned concomitant intra-operative procedures (except for closure of patent foramen ovale or atrial septal defect or coronary revascularization) * Planned concomitant intra-operative Maze procedure for symptomatic paroxysmal atrial fibrillation. * Persistent atrial fibrillation * Prior mitral valve repair * Contraindication for cardiopulmonary bypass * Clinical signs of cardiogenic shock * ST segment elevation myocardial infarction within 14 days prior to inclusion in this study. * Congenital heart disease (except PFO or ASD) * Chronic renal insufficiency defined by Creatinine ≥ 3.0 or chronic renal replacement therapy, who are contraindicated for cardiac surgery * Recent history of psychiatric disease that is likely to impair compliance with the study protocol, in the judgement of the investigator * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in left ventricular function as assessed by LVEF | Baseline, up to 5 years | Change in Left Ventricular Ejection Fraction (LVEF) will be reported as a change in percent ejection fraction assessed via echocardiogram |
| Change in left ventricular volume | Baseline, up to 5 years | End systolic and end diastolic left ventricular volumes will both be evaluated in mL using echocardiogram. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants at each FMR severity grade | Baseline, up to 5 years | Functional Mitral Regurgitation (FMR) severity is graded on a scale of 1 to 4 with 1 = none, 2 =mild, 3 = moderate and 4 =severe. This outcome will report the percentage of participants with reported none, mild, moderate or severe mitral regurgitation as assessed via echocardiogram by treating physician. |
| Change in MLHF Questionnaire Score | Baseline, up to 5 years | Minnesota Living with Heart Failure (MLHF) is a 21-item questionnaire with a total score ranging from 0 (indicating heart failure has no affect to life) to 105 (indicating the greatest affect to life). |
| Change in Functional Status as assessed by 6MWT | Baseline, up to 5 years | Functional status will be assessed as the distance reached in meters via the 6-minute Walk Test (6MWT). |
| Mortality Rate | 5 years | Rate of reported mortality rate will be evaluated. |
| Heart Failure Readmission Rate | 5 years | Heart failure readmission rate will be calculated for heart failure throughout the duration of study participation. |
| Incidence of Mitral Leaflet Tenting | 5 years | Mitral Leaflet tenting will be evaluated using echocardiographic imaging. |
| All Cause Readmission Rate | 5 years | All cause readmission rate will be calculated for any case throughout the duration of study participation. |
| Number of Major Adverse Cardiac Events (MACE) | 5 years | MACE is defined as a composite of clinical events comprised of death, stroke, worsening heart failure defined as +1 New York Heart Association (NYHA) class, Congestive Heart Failure (CHF) hospitalization and mitral valve intervention as evaluated by treating physician |
Outcome results
None listed